TP53 limits erastin-induced ferroptosis by blocking dipeptidyl-peptidase-4 (DPP4) activity, while silencing TP53 results in increased ferroptosis in CRC cells and enhancing the anti-tumor activity in mouse models [117]. This evidence concerns the gene TP53 and neoplasm.